Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Australia
Scientia Clinical Research Ltd, Randwick, New South Wales Calvary Mater Newcastle, Waratah, New South Wales Icon Cancer Centre South Brisbane, South Brisbane, Queensland Cancer Research SA Pty Ltd, Adelaide, South Australia Linear Clinical Research, Nedlands, Western Australia Last updated February 2026